Abstract 199P
Background
Cervical cancer is the third most frequent disease among women in the world, which accounts for more than 9% of the total number of newly diagnosed malignant neoplasms in the female population, with more than 85% of newly diagnosed cervical cancer cases seen in developing countries. In the Republic of Uzbekistan, cervical cancer remains the most common cancer type and the leading cause of cancer death.
Methods
To analyze the cervical cancer burden we collected incidence data and TNM stage on cervical cancers from official statistics from Uzbekistan for years 2010-2019.
Results
In the structure of the general oncological morbidity over the last 10 years, cervical cancer takes 3rd place, but among the female population 2nd place. Analysis of the number of cervical cancer cases shows that over the 10-year period there were registered 14 499 (6.9%) new cervical cancer cases and 210 881 cases of all malignant neoplasms. Incidence rate tended to increase from 4.3in 2010 to 5.6 in 2019 per 100 thousand population. For the period 2010-2019 the age category of patients with cervical cancer was distributed as follows: patients under 15 years old were 1 (0.01%), at the age of 15-17 years - 4 (0.03%), from 18-44 years - 3777 (26 , 1%), 45-64 years old - 8963 (61.8%), 65 years and older - 1754 (12.1%). In 2010 and 2019, over 41% and 28% cervical cancers in Uzbekistan were registered at stages III-IV, but 57.8% and 67.0% cervical cancers were registered at stages I-II accordingly. Moreover 7 662 patients died from cervical cancer over the last 10 years, while the mortality rate was 2.3 in 2010, and 3.0 in 2019 per 100 thousand population.
Conclusions
In conclusion it can be shown that cervical cancer morbidity has the tendency to increase in the Republic of Uzbekistan. 45-65-year-old women are more likely to develop cervical cancer in the Republic. Over the last 10 years, there has been a decrease of advanced (III-IV) stages of cervical cancer cases. The increase in morbidity is due to implementation of modern diagnostic methods, creation and use of diagnostic and treatment standards.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - Dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity modulated radiotherapy to ipsilateral neck
Presenter: Manish Chomal
Session: Poster viewing 03
238P - Proposing a predictive nomogram for lymph-node metastasis (LNM) in oral squamous cell carcinoma (OSCC) using immunohistochemical marker D2-40
Presenter: Karen Boaz
Session: Poster viewing 03
239P - Prospective evaluation of difference in patient-reported swallowing outcomes and quality of life of tongue vs bucco-alveolar complex cancers treated with ablative surgery
Presenter: Abhinav Thaduri
Session: Poster viewing 03
240P - SERPINE2 promotes the growth, invasion, and metastasis in oral squamous cell carcinoma and is associated with poor prognosis
Presenter: Hao-Wen Chuang
Session: Poster viewing 03
241P - P16 IHC stain is an useful marker for predicting outcome of oropharyngeal cancer in Taiwan
Presenter: chiencheh chen
Session: Poster viewing 03
242P - Epidemiology and survival analysis of head and neck cancer: Results from a comprehensive care center in North India
Presenter: Amit Badola
Session: Poster viewing 03
243P - Induction bio-chemotherapy or bio-chemoimmunotherapy for locally advanced betel-nut-related HNSCC in Taiwan
Presenter: Jo Pai Chen
Session: Poster viewing 03
244P - Alternate-day hypofractionated radiotherapy for radical treatment of head & neck cancer during the COVID-19 pandemic: A single institute experience
Presenter: Pragya Singh
Session: Poster viewing 03
246P - Clinicoepidemiological profile and patterns of failure in carcinoma oral cavity in Indian patients: A 6-year retrospective study
Presenter: Aashita -
Session: Poster viewing 03